Skip to main content
OpenTrials
Completed

NCT Number: NCT05664672

Study to Evaluate Changes in Smokers Using on!® Nicotine Pouches

The purpose of this study is to generate evidence regarding the extent of reduction in exposure to selected HPHCs in adult smokers switching to on!® NPs. The study intends to determine changes in exposure to selected HPHCs by measuring biomarkers in adult smokers who completely switch from smoking to use of on!® NP compared to those who continue smoking cigarettes or stop using all tobacco products.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Tobacco Use Behavior Smoking

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CKRA, Lexington, Kentucky, United States

Loading trial locations.

About this study

This is an open-label, randomized, 5 parallel-group clinical study evaluating changes in exposure to selected harmful and potentially harmful constituents (HPHCs) and product use behavior in adult smokers who are randomly assigned to 1 of the 5 groups; continue smoking, partially or completely switch to oral tobacco-derived nicotine products, or stop using any tobacco products for 7 days.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Voluntary consent to participate in this study documented on the signed ICF
  • Smoking history (self-reported at screening) of an average of at least 10 but no more than 30 factory-manufactured combustible cigarettes (either menthol or non-menthol) daily for at least 12 months prior to screening. Brief periods (ie, up to 7 consecutive days) of non-smoking during the 3 months prior to screening (eg, due to illness or participation in a study where smoking was prohibited) will be permitted
  • Positive urine cotinine (≥ 500 ng/mL) at screening
  • Female subjects who are heterosexually active and of childbearing potential (eg, neither surgically sterile at least 6 months prior to check-in nor postmenopausal with amenorrhea for at least 12 months prior to check-in with follicle-stimulating hormone [FSH] levels consistent with postmenopausal status) must have been using one of the following forms of contraception for the time period indicated and agree to continue using it through completion of the study:
  • Hormonal (eg, oral, vaginal ring, transdermal patch, implant, injection) consistently for at least 3 months prior to check-in, double barrier (ie, condom with spermicide or diaphragm with spermicide) consistently for at least 4 weeks prior to check-in, an intrauterine device for at least 4 months prior to check-in
  • Exclusive partner who has been vasectomized for at least 6 months (inclusive) prior to check-in

Female subjects of childbearing potential who are not currently engaging in heterosexual intercourse must agree to use one of the above methods of birth control through completion of study, in the event that they have heterosexual intercourse during the course of the study.

  • Female subjects who are of nonchildbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to check-in:

Hysteroscopic sterilization (including Essure® or similar nonsurgical sterilization procedures); bilateral tubal ligation or bilateral salpingectomy; hysterectomy; bilateral oophorectomy

Or be postmenopausal with amenorrhea for at least 12 months prior to check-in and have FSH levels consistent with postmenopausal status

  • Willing to comply with the requirements of the study
  • Willing to use all 3 on!® NP after the Product Trial at check-in
  • Willing and able to abstain from cigarettes from Day 1 through the end of the study (EOS)
  • Healthy adult males and females, 21 to 65 years of age, inclusive at screening, with subjects aged 46 to 65 years being fully vaccinated for COVID-19 (SARS-CoV-2) at least 14 days before the screening visit.

Exclusion criteria

  • Use of any type of tobacco- or nicotine-containing products other than manufactured cigarettes (eg, e-vapor products, roll-your-own cigarettes, bidis, snuff, nicotine inhaler, pipe, cigar, chewing tobacco, nicotine patch, nicotine spray, nicotine lozenge, or nicotine gum) in the 7 days prior to check-in
  • Self-reported puffers (ie, adult smokers who draw smoke from the cigarette into the mouth and throat but do not inhale)
  • Planning to quit smoking in the next 30 days (from screening visit)
  • History or presence of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, existing respiratory diseases, immunologic, psychiatric, lymphatic, or cardiovascular disease, or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
  • Clinically significant abnormal findings on the vital signs, physical examination, medical history, electrocardiogram (ECG), or clinical laboratory results, in the opinion of the investigator
  • Positive test for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus at screening
  • History or presence of any type of malignant tumors
  • Current evidence or any history of congestive heart failure
  • Diabetes mellitus (fasting glucose ≥126 mg/L [7 mmol/L]) that is not controlled by diet/exercise alone, in the opinion of the investigator
  • An acute illness (eg, upper respiratory infection, viral infection) requiring treatment with prescribed medicines within 2 weeks prior to check-in
  • Dentition that prevents subjects from using on!® NP products
  • Allergic to or cannot tolerate mint flavoring agents or phenylalanine
  • Any planned surgery from the time of screening through EOS
  • History of drug or alcohol abuse within 24 months prior to check-in
  • Fever (ie, body temperature >100.5°F) at screening or check-in. One recheck may be performed at the investigator's discretion
  • Body mass index greater than 40.0 kg/m2 or less than 18.0 kg/m2 at screening
  • Systolic blood pressure >150 mmHg and/or diastolic blood pressure > 90 mmHg at screening or check-in, measured after being seated for at least 5 minutes. One recheck may be performed at the investigator's discretion
  • Estimated creatinine clearance (by Cockcroft-Gault equation) < 80 mL/minute at screening
  • Serum alanine aminotransferase ≥1.5 times the upper limit of normal and/or aspartate aminotransferase ≥1.5 times the upper limit of normal at screening
  • Positive screen for alcohol (breath) or any of the following drugs of abuse (urine), regardless of the reason of use: amphetamines, methamphetamines, opiates, cannabinoids, or cocaine at screening or check-in
  • Female subjects who are pregnant (positive serum pregnancy test at screening or urine pregnancy test at check-in), lactating, or intend to become pregnant from screening through EOS
  • Use of prescription or over-the-counter bronchodilator medication (eg, inhaled or oral ß-agonists) within 12 months prior to check-in
  • Use of medications or foods known or are suspected to interact with cytochrome P450 2A6 (including, but not limited to, amiodarone, amlodipine, amobarbital, buprenorphine, clofibrate, clotrimazole, desipramine, disulfiram, entacapone, fenofibrate, isoniazid, grapefruit, ketoconazole, letrozole, methimazole, methoxsalen, metyrapone, miconazole, modafinil, orphenadrine, pentobarbital, phenobarbital, pilocarpine, primidone, propoxyphene, quinidine, rifampicin, rifampin, secobarbital, selegiline, sulconazole, tioconazole, tranylcypromine) within 14 days or 5 half-lives of the drug, whichever is longer, prior to check-in or during the study
  • Use of antibiotic treatment within 2 weeks prior to check-in
  • Plasma donation within 7 days prior to check-in
  • Donation of blood or blood products (with the exception of plasma as noted above), had significant blood loss, or received whole blood or a blood product transfusion within 56 days prior to check-in
  • Participation in a previous clinical study for an investigational drug, device, biologic, or a tobacco product within 30 days prior to check-in
  • Participation in 2 or more Altria Client Services (ALCS) studies within the past 12-month period prior to check-in
  • Subject or a first-degree relative (ie, parent, sibling, child, spouse/partner) is a current or former employee of the tobacco industry or a named party or class representative in litigation with any tobacco company
  • Subject or a first-degree relative (ie, parent, sibling, child, spouse/partner) is a current employee of the study site
  • Positive result for coronavirus disease (COVID)-19 (SARS-CoV-2) test at screening or check-in
  • One or more "yes" answers to any of the questions on the COVID-19 (SARS-CoV-2) screening questionnaire (provided by the study site) at screening or check-in.
  • Have been diagnosed with major depressive disorder or have a history of suicide attempt.

Treatment and study plan

OTDN Product 1

Other

Mint on!® 2 mg nicotine pouches

OTDN Product 2

Other

Mint on!® 4 mg nicotine pouches

OTDN Product 3

Other

Mint on!® 8 mg nicotine pouches

No Tobacco

Other

subjects completely stop all tobacco product usage for 7 days

Primary outcomes

  1. NNAL Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

Secondary outcomes

  1. NE Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted Nicotine Equivalents (NE) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during the 24 hours was converted to 24-hour urine volume using the assumed density of 1 gram (g) equals 1 milliliter (mL).

    The amount of biomarker was calculated as follows:

    NE concentration (μg/mL) = (nicotine [ng/mL]/162.23 [mg/mmol] + nicotine-gluc [ng/mL]/338.36 [mg/mmol] + cotinine [ng/mL]/176.22 [mg/mmol] + cotinine-gluc [ng/mL]/352.34 [mg/mmol] + trans-3'-hydroxycotinine [ng/mL]/192.22 [mg/mmol] + trans-3'-hydroxycotinine-gluc [ng/mL]/368.34 [mg/mmol]) × 162.23 (mg/mmol) × 1 μg/1000 ng

    Adjusted Nicotine equivalents (mg NE/g creatinine) = NE concentration (μg/mL) × 100 / Creatinine concentration (mg/dL)

    Absolute change from baseline = Post Randomization Value - Baseline Value

  2. 2-AN Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted 2-aminonaphthalene (2-AN) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  3. 4-ABP Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted 4-aminobiphenyl (4-ABP) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  4. HEMA Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted 2-hydroxyethylmercapturic acid (HEMA) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  5. CEMA Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted cyanoethylmercapturic acid (CEMA) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  6. SPMA Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted S-phenylmercapturic acid (SPMA) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  7. HMPMA Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted 3-hydroxy-1-methylpropylmercapturic acid (HMPMA) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  8. 3-HPMA Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted 3-hydroxypropylmercapturic acid (3-HPMA) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  9. 2-HPMA Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted 2-hydroxypropylmercapturic acid (2-HPMA) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  10. AAMA Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted N-acetyl-S-(2-carbamoylethyl) cysteine (AAMA) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  11. GAMA Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted N-acetyl-S-(2-carbamoyl-2-hydroxyethyl)-1-cysteine (GAMA) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  12. 2-MHBMA Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted 2-hydroxybutenylmercapturic acid (2-MHBMA) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  13. 2-OH-Flu Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted 2-OH-Fluorene (2-OH-Flu) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  14. 2-OH-Nap Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted 2-Naphthol (2-OH-Nap) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  15. 1-OH-Phe Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted 1-OH-Phenanthrene (1-OH-Phe) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  16. 3-OH-B[a]P Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted 3-hydroxybenzo[a]pyrene (3-OH-B[a]P) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  17. Urine Mutagenicity Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urine mutagenicity (Rev/24h) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    250 mL urine sample will be concentrated to 1 mL and used for urine mutagenicity testing.

    Measurement results are reported as revertants/μL. Urine mutagenicity count in the 24-hour urine was calculated as:

    Urine mutagenicity (revertants/250 mL) = Urine mutagenicity (revertants/μL) x 1000V, where V is the volume after concentration in mL

    Urine mutagenicity (revertants/24 hour) = Urine mutagenicity (revertants/250 mL) x [24h urine volume(mL) ÷ V], where V is the volume in mL of urine sample used for the mutagenicity test

  18. 1-OH-Pyr Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected over 24 hours on Day -1 (baseline) and Day 7

    Summary of 24-hour urinary creatinine-adjusted 1-hydroxypyrene (1-OH-Pyr) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    Total urine weight (g) collected during 24 hours was converted to 24-hour urine volume using assumed density of 1 g = 1 mL

    Amount of biomarker was calculated as:

    Urine Biomarker (unit2/24 hours) = Urine biomarker concentration [unit1/mL] × 24h urine volume [mL] ÷ 1000, where: unit2 = ng if unit1 = pg; unit2 = μg if unit1 = ng

    Adjusted Urine biomarker (unit2/g creatinine) = Urine biomarker concentration (unit1/mL) × 100 / Creatinine concentration (mg/dL), where unit2 = ng if unit1 = pg, and unit2 = μg if unit 1 = ng

    The absolute change from baseline of urine biomarker amount excreted in 24 hours was calculated as follows:

    Absolute change from baseline = Post Randomization Value - Baseline Value

  19. Carboxyhemoglobin (COHb) Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days

    Time frame: Samples collected at approximately 21:30 on Day -1 (baseline) and Day 7

    Summary of blood carboxyhemoglobin (%) in subjects using nicotine pouches (NP) for 7 days versus subjects who continue to smoke cigarettes for 7 days and subjects who stopped using any tobacco products for 7 days.

    The absolute change from baseline of urine biomarker amount excreted in 24 hours and blood biomarker concentration will be calculated as follows: Absolute change from baseline = Post Randomization Value - Baseline Value where Baseline = Day -1

  20. Summary of Cigarettes Smoked Per Day (CPD)

    Time frame: Data was collected from 07:00 to 23:00 each day starting from Day 1 to Day 7/end of study

    The number of cigarettes smoked per day (CPD) from 07:00 to 23:00 on Day 1 to Day 7 was collected to assess produce use behavior. Subjects in NP2, NP4, NP8 and NT groups were not allowed to use cigarettes starting at Day 1.

  21. Summary of Total Number of Nicotine Pouches Used Per Day (NPPD)

    Time frame: Data was collected from 07:00 to 23:00 each day starting from Day 1 to Day 7/end of study

    The number of nicotine pouches used per day (NPPD) from 07:00 to 23:00 on Day 1 to Day 7 was collected to assess produce use behavior. Only subjects in NP2, NP4 and NP8 groups used nicotine pouches during the study.

  22. Summary of Average Number of Nicotine Pouches Per Use

    Time frame: Data was collected from 07:00 to 23:00 each day starting from Day 1 to Day 7/end of study

    The average number of nicotine pouches per use occasion (NPPU) from 07:00 to 23:00 on Day 1 to Day 7 was collected to assess produce use behavior. Only subjects in NP2, NP4 and NP8 groups used nicotine pouches during the study.

  23. Summary of Average Duration of Each Nicotine Pouch Use

    Time frame: Data was collected from 07:00 to 23:00 each day starting from Day 1 to Day 7/end of study

    The average duration (in minutes) of each nicotine pouch use from 07:00 to 23:00 on Day 1 to Day 7 was collected to assess produce use behavior. Only subjects in NP2, NP4 and NP8 groups used nicotine pouches during the study.

Sponsors and collaborators

Lead sponsor

Altria Client Services LLC

Industry

Collaborators

  • Covance

Registry information

Official study title

A Randomized, Controlled, Open-label Short-term Study to Evaluate Changes in Exposure to Harmful and Potentially Harmful Constituents in Adult Smokers Who Completely Switch to on!® Nicotine Pouches in a Clinical Setting

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Dec 27, 2022
Registry last updated
Dec 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.